Cargando…

Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report

BACKGROUND: Immunosuppressive therapy has been—until the recent release of new guidelines on diagnosis and management—the recommended treatment for idiopathic pulmonary fibrosis. However, its efficacy in patients with idiopathic pulmonary fibrosis has always been a matter of debate. CASE PRESENTATIO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cerri, Stefania, Sgalla, Giacomo, Richeldi, Luca, Luppi, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937572/ https://www.ncbi.nlm.nih.gov/pubmed/27387033 http://dx.doi.org/10.1186/s13256-016-0916-5

Ejemplares similares

Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?
por: Sgalla, Giacomo, et al.
Publicado: (2020)

The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials?
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis: pathogenesis and management
por: Sgalla, Giacomo, et al.
Publicado: (2018)

COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
por: De Biasi, Sara, et al.
Publicado: (2015)

Better to Be an Agnostic than a Believer (at Least in Pulmonary Fibrosis)
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis: moving forward
por: Richeldi, Luca
Publicado: (2015)

Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review
por: Luppi, Fabrizio, et al.
Publicado: (2015)

GATA1-defective immune-megakaryocytes as possible drivers of idiopathic pulmonary fibrosis
por: Gobbo, Francesca, et al.
Publicado: (2023)

Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment
por: Cottin, Vincent, et al.
Publicado: (2014)

Reply to Huang and Wei, Kang et al., and Ehteshami-Afshar and Raj
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy
por: Sgalla, Giacomo, et al.
Publicado: (2015)

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions
por: Ferrara, Giovanni, et al.
Publicado: (2018)

Road Toward a New Model of Care for Idiopathic Pulmonary Fibrosis in the Lazio Region
por: Di Bidino, Rossella, et al.
Publicado: (2022)

Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis
por: Jones, Mark G., et al.
Publicado: (2016)

Genetic testing in diffuse parenchymal lung disease
por: Spagnolo, Paolo, et al.
Publicado: (2012)

Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
por: Casillo, Valeria, et al.
Publicado: (2019)

Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges
por: Spagnolo, Paolo, et al.
Publicado: (2012)

Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
por: Rochwerg, Bram, et al.
Publicado: (2016)

“Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease
por: Sgalla, Giacomo, et al.
Publicado: (2018)

Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don’t
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome?
por: Marchioni, Alessandro, et al.
Publicado: (2018)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Identifying the Risk of Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Step Forward
por: Vancheri, Carlo, et al.
Publicado: (2022)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials
por: Collard, Harold R, et al.
Publicado: (2013)

Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2015)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2019)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics
por: Costabel, U, et al.
Publicado: (2013)

Correction to: Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2021)

Differences between Acute Exacerbations of Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
por: Faverio, Paola, et al.
Publicado: (2021)

Telomere Shortening Is behind the Harm of Immunosuppressive Therapy in Idiopathic Pulmonary Fibrosis
por: Molina-Molina, Maria
Publicado: (2019)

Reply to Moran-Mendoza: Idiopathic Pulmonary Fibrosis Update. Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?
por: Raghu, Ganesh, et al.
Publicado: (2022)

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2022)

Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis
por: Wallis, Tim JM, et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management
por: Luppi, Fabrizio, et al.
Publicado: (2021)

Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
por: Zhang, David, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6itq9odcba6q5utcrq5hknjdmn